| Distinct Uroplakin II Staining Pattern in Apocrine Breast Carcinoma. | Distinct Uroplakin II Staining Pattern in Apocrine Breast Carcinoma.
van Pel DM, Pors J, Yuen E, Chan R, Kos Z, Hayes MM, Wang G. | 11/19/2022 |
| Uroplakin II as a single marker for luminal versus basal molecular subtypes in muscle invasive urothelial carcinoma. | Uroplakin II as a single marker for luminal versus basal molecular subtypes in muscle invasive urothelial carcinoma.
Pryma C, Villamil C, Gibb EA, Oo HZ, Seiler R, Contreras-Sanz A, Douglas J, Black PC, Wang G. | 10/15/2022 |
| Expression of uroplakin II and GATA-3 in bladder cancer mimickers: caveats in the use of a limited panel to determine cell of origin in bladder lesions. | Expression of uroplakin II and GATA-3 in bladder cancer mimickers: caveats in the use of a limited panel to determine cell of origin in bladder lesions.
Leivo MZ, Tacha DE, Hansel DE. | 01/1/2022 |
| Uroplakin II was immunopositive in 53% and 60% of urothelial carcinomas (UC) of the bladder and the ureter, respectively. | Diagnostic Utility of Prostein, Uroplakin II and SATB2 for Diagnosing Carcinoma of Unknown Primary Origin: A Systematic Immunohistochemical Profiling.
Mochizuki K, Kawai M, Odate T, Tahara I, Inoue T, Kasai K, Nakazawa T, Katoh R, Kondo T. | 08/11/2018 |
| These results suggest that whereas GATA-3 and uroplakin II may be most useful in the diagnosis of urothelial carcinoma metastasis, p40 may be additionally suited as a prognostic marker. | A combination of p40, GATA-3 and uroplakin II shows utility in the diagnosis and prognosis of muscle-invasive urothelial carcinoma.
Leivo MZ, Elson PJ, Tacha DE, Delahunt B, Hansel DE. | 04/8/2017 |
| UPII, GATA3, and p40, when used in combination, are highly sensitive in the differential diagnosis of invasive urothelial carcinoma. | Uroplakin II (UPII), GATA3, and p40 are Highly Sensitive Markers for the Differential Diagnosis of Invasive Urothelial Carcinoma.
Hoang LL, Tacha D, Bremer RE, Haas TS, Cheng L. | 09/3/2016 |
| UPII was highly specific/moderately sensitive for urothelial carcinoma. May be a potentially useful marker to identify urothelial lineage and help distinguish UC from prostate cancer or, in conjunction with GATA3, from metastatic breast cancer. | Utility of uroplakin II expression as a marker of urothelial carcinoma.
Tian W, Guner G, Miyamoto H, Cimino-Mathews A, Gonzalez-Roibon N, Argani P, Li X, Sharma R, Subhawong AP, Rezaei K, Bivalacqua TJ, Epstein JI, Bishop JA, Netto GJ. | 02/14/2015 |
| UPII demonstrates a significantly higher sensitivity than UPIII in conventional and variant urothelial carcinomas | Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants.
Li W, Liang Y, Deavers MT, Kamat AM, Matin SF, Dinney CP, Czerniak B, Guo CC. | 01/10/2015 |
| Uroplakin II antibody BC21 demonstrated superior sensitivity and specificity in urothelial carcinoma, compared with uroplakin III, suggesting an advantage in differential diagnosis of urothelial carcinoma and in the detection of tumors of unknown origin. | A newly developed uroplakin II antibody with increased sensitivity in urothelial carcinoma of the bladder.
Hoang LL, Tacha DE, Qi W, Yu C, Bremer RE, Chu J, Haas TS, Cheng L. | 09/27/2014 |
| combination of prostate stem cell antigen enhancer and uroplakin II promoter is feasible in constructing bladder cancer-specific vectors | Prostate stem cell antigen enhancer and uroplakin II promoter based bladder cancer targeted tissue-specific vector.
Wang D, Wang Z, Tian J, He X, Chowdhury WH, Zhang X, Li S, Rodriguez R. | 06/28/2010 |
| study offers no definitive support for uroplakin II mutations causing human renal tract malformations | Mutation analyses of Uroplakin II in children with renal tract malformations.
Jenkins D, Bitner-Glindzicz M, Malcolm S, Allison J, de Bruyn R, Flanagan S, Thomas DF, Belk RA, Feather SA, Bingham C, Southgate J, Woolf AS. | 01/21/2010 |